🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2025-524310-28-00
Authorised Phase I

A Study Evaluating the Safety and Tolerability of a Novel Formulation of QRL-101 in Healthy Participants

2025-524310-28-00 · tracked via the Priya Life Science EU tracker
Sponsor
Quralis Corp.
Sponsor type
Pharmaceutical company
Therapeutic area
Nervous System Diseases
Decision date
23/01/2026
Enrollment target
48
Sites
Netherlands

Condition studied

Epilepsy, amotrophic lateral sclerosis, neuropathy

Eligibility

Age group
18-64 years, 65+ years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-524310-28-00 on CTIS ↗ ← All trials in the EU